-
Jackie Fairley, BVSc, BSc, MBA, chief executive officer of Starpharma of Victoria, Australia, recently fielded some questions from AIDS Alert about the company's investigational microbicide, VivaGel.®
-
As if HIV clinics and physicians didn't have enough government paperwork and bureaucracy to worry about, the nearly three-year-old Medicare Part D prescription drug coverage offers a labyrinth of obstacles, pitfalls, and other problems in keeping HIV patients adherent to their antiretroviral treatment (ART).
-
Some of the concerns and predictions HIV/AIDS advocates made two years ago about the impact of Medicare Part Dthe prescription drug benefiton HIV antiretroviral treatment appear to be coming true.
-
-
Increased migraine attack frequency and overuse of acute medication, especially barbiturates and opiates, are risk factors for the chronification of migraine, which occurs in up to 2% of individuals.
-
The Babinski sign continues to be a valid bed-side test for pyramidal tract lesions.
-
A randomized, controlled trial in the Netherlands showed that oral prednisolone and naproxen were equivalent in the treatment of acute gout with no difference in side effects.
-
Perhaps the most prominent cardiovascular report in 2007 was the publication of the COURAGE trial (N Engl J Med. 2007;356:1503-1516), which demonstrated the equality in major CV outcomes in randomized patients with stable CAD, most with angina, who were assigned PCI with optimal medical therapy (OMT) vs OMT alone, with a mean follow-up of 4.6 years.
-
In a prospective study of immunocompetent patients admitted to critical care units, CMV viremia showed a significant association with prolonged ICU stay and death.
-
This study showed that intra-abdominal hypertension is associated with increased organ dysfunction and higher ICU mortality, and two commonly used methods for measuring intra-abdominal pressure have equivalent predictive capabilities.